Allogene Therapeutics Inc

Following a Stage 1 consolidation attempt after a terminal decline, the stock exhibits a repaired EMA regime yet remains under an active Lower Highs & Lower Lows pattern, reinforcing a medium-term bearish bias. In the short term, price is tightly tracking above the rising 9/21-EMA zone without a clear rejection signal, arguing for patience and deferred execution until a more decisive breakdown or EMA rejection occurs.

• ↑Phase 2 ALPHA3 trial cema-cel shows 58.3% MRD negativity vs 16.7% control.
• ↑FDA granted RMAT and Fast Track designations, expediting approval path.
• ↓Negative earnings yield and profitability scores signal weak returns.